echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Chinese medicine tablet industry maintained a high-speed growth trend, achieving a profit of nearly 7.9 billion yuan in the first half of the year

    The Chinese medicine tablet industry maintained a high-speed growth trend, achieving a profit of nearly 7.9 billion yuan in the first half of the year

    • Last Update: 2022-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Traditional Chinese medicine tablets are one of the three pillars of China's traditional Chinese medicine industry, and the Chinese medicine tablet industry has always been included in the scope of national key protection and is an important part
    of the Chinese medicine industry.
    In recent years, the demand for Chinese medicine tablets has been growing, playing an increasingly important role
    in the field of medicine and health.

     
    Data show that the Chinese medicine tablet industry is maintaining a high-speed growth trend
    .
    Among them, from the perspective of the revenue of the Chinese medicine tablet industry by quarter, the revenue of the Chinese medicine tablet industry in the first quarter of 2022 increased by 9.
    15% year-on-year to 49.
    4 billion yuan; In the second quarter, the revenue increased by 5.
    14% year-on-year to 51.
    1 billion yuan.

    In total, in the first half of this year, the revenue of the Chinese medicine tablet industry increased by 6.
    99% year-on-year to 100.
    5 billion yuan.

    In both quarters, the Chinese medicine tablet industry showed steady growth and higher than that of the proprietary Chinese medicine industry
    .

     
    From the perspective of profit, the profit of the traditional Chinese medicine tablet industry in the first quarter of this year increased by 31.
    6% year-on-year to 4.
    2 billion yuan, continuing to maintain a substantial growth trend; In the second quarter, the profit of the Chinese medicine tablet industry increased by 10.
    5% year-on-year to 3.
    68 billion yuan
    .
    In total, in the first half of this year, the profit of the Chinese medicine tablet industry increased by 20.
    3% year-on-year to 7.
    88 billion yuan
    .

     
    The Chinese medicine tablet industry has always been included in the scope of national key protection, is an important part of the Chinese medicine industry, plays a key role in carrying forward the upper and lower levels, and is also a strategic industry
    in China.
    With the enhancement of people's health awareness and the deepening of their understanding of Chinese medicine tablets, the demand for Chinese medicine tablets is growing and playing an increasingly important role
    .

     
    In addition, the industry predicts that 33.
    27% of the future consumption of young people aged 18-25 will be used in medical care, and young people have become a group of people
    with potential for health.
    It is foreseeable that the category of Chinese medicine tablets will become a new growth engine
    for pharmacies.

     
    It is understood that in order to better promote the development of the Chinese medicine tablet industry, in recent years, China has also continuously improved the quality of Chinese medicine tablets, of which in the national multi-departmental coordination, multiple measures at the same time, optimize the layout of Chinese herbal medicine production areas, build authentic medicinal materials breeding base, ecological planting base, and promote the construction and use of Chinese medicine quality traceability system; Under the background of strengthening the technical guidance of Chinese herbal medicine planting, controlling the use of agricultural inputs, and promoting the standardized planting and ecological planting of Chinese herbal medicines, the State Food and Drug Administration's 2021 National Drug Sampling Annual Report shows that the total pass rate of Chinese medicine tablets sampling has reached 98%.


     
    The industry said that in recent years, the State Food and Drug Administration and local drug regulatory departments have been strengthening the quality supervision of Chinese medicine tablets, and there are many cases of fines for the production of unqualified tablets
    .
    In addition to strengthening supervision, the state has also promoted the standardized development
    of the Chinese medicine tablet industry by continuing to promote GAP certification and upgrading pharmacopoeia requirements.
    In addition, the awareness of enterprises in improving the quality of traditional Chinese medicine tablets has also been continuously enhanced
    .

     
    If some enterprises say that in the process of enterprise production and construction, the company always regards drug quality as the core competitiveness of enterprises, strictly implements the GMP technical specifications and standards of traditional Chinese medicine tablets, actively promotes the application of new technologies, new processes, new materials and new equipment of traditional Chinese medicine tablets, and continuously promotes process improvement, so as to achieve high-quality development
    of traditional Chinese medicine tablets.

     
    In the future, as the state increases its support for the traditional Chinese medicine industry, the development space of the Chinese medicine tablet market will increase; At the same time, with the gradual improvement of the quality standards of traditional Chinese medicine tablets and the tightening of industry supervision, small enterprises will be under pressure and gradually eliminated, and large-scale and standardized enterprises will benefit from the test of the regulatory system, and the concentration of the entire industry is expected to increase
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.